Summary
The Delhi High Court ruled in favor of Dr Reddy's Labs, ordering the removal of Razenta Pharmaceuticals' Daplogin trademark due to its deceptive similarity to Dr Reddy's Daplo. The court cited phonetic similarity and potential consumer confusion for the Type-2 diabetes drugs, cancelling Razenta's trademark registration.